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Pityriasis rubra pilaris (PRP) is an inflammatory skin 
condition characterized by well-circumscribed hyperke-
ratotic plaques and palmoplantar keratoderma (1). The 
aetiology of PRP is unclear and although various treat-
ment options, such as topical steroids and oral retinoic 
acids, are available, treatment responses are inconsistent 
and management is often difficult (2). We report here a 
case of PRP that was treated successfully with apremilast, 
a phosphodiesterase-4 (PDE4) inhibitor. Furthermore, 
using immunohistochemistry we examined the expres-
sion of nuclear factor of kappa light chain enhancer in B 
cells (NF-κB) and caspase recruitment domain family, 
member 14 (CARD14), a molecule that induces acti-
vation of NF-κB and is reported to be involved in the 
pathogenesis of PRP in the skin.
CASE REPORT
A 60-year-old woman with no significant medical or 
family history attended our clinic 4 years ago with a 
1-month history of well-demarcated, pruritic erythema 
keratodes on the hands, soles of the feet, elbows, and 
knees (Fig. 1a). Keratinizing papules on the palms, and 
scales on the dorsa of the hands and nail beds, were also 
seen. No nail-fold capillary abnormalities or nail changes 
were evident, and she had no systemic symptoms. Skin 
biopsy at initial presentation showed a “chequerboard 
pattern” of alternating parakeratosis and orthokerato-
sis, irregularly elongated rete ridges, acantholysis, and 
dermal melanin incontinence (Fig. 2a). Based on the 
clinical and histological findings, she was diagnosed 
with type I PRP. She developed mild arthralgia 5 months 
later and was referred to the rheumatology department. 
Her autoantibody screening showed an elevated anti-
centromere antibody and limited cutaneous systemic 
sclerosis was diagnosed, but no additional treatments 
were started by the rheumatologists. Over the following 
4 years all strengths of topical steroid ointments, topical 
vitamin D3 analogues and salicylic acid, oral retinoic 
acid, and phototherapy were tried. Other treatments, 
such as methotrexate, were not considered due to pos-
sible side-effects. Although mild improvements were 
seen throughout the treatment period, the skin lesions 
always recurred and never completely resolved. As the 
symptoms were refractory, our treatment options were 
limited and we decided to start apremilast at 30 mg/day. 
Although no substantial changes in the hyperkeratosis 
of the feet were seen one month after the introduction of 
apremilast, significant improvements were seen after 2 
months. Currently, the skin lesions have not shown any 
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Fig. 1. Clinical presentation of pityriasis rubra pilaris before and 
after treatment with apremilast. (a) Keratinization and erythema 
were seen on both feet and knees at initial presentation. (b) Significant 
improvements in the skin lesions were seen at 6 months after the start of 
treatment with apremilast.
Fig. 2. Histological presentation and immunohistochemical staining of pityriasis rubra pilaris for p65 and CARD14. (a) Haematoxylin and 
eosin staining of the skin biopsy shows the classic “chequerboard appearance” of alternating parakeratosis and orthokeratosis (original magnification 
×5; scale bar=500 mm). (b) Skin biopsy stained for p65 shows nuclear staining in keratinocytes (white circle) and in inflammatory cells surrounding the 
vasculature (black square). (original magnification ×10; scale bar=250 mm). (c) Skin biopsy stained for CARD14. Weak expressions of CARD14 were 


























































recurrence at 6 months of treatment with apremilast (Fig. 
1b) and the patient has only experienced mild headaches, 
a common adverse event associated with apremilast, 
which was manageable with oral analgesia.
As apremilast is thought to suppress the activation of 
NF-κB, a transcriptional factor that induces various in-
flammatory mediators, and as recent studies have shown 
that the expression of CARD14, an important molecule 
for NF-κB activation, in keratinocytes is upregulated in 
PRP (3), we investigated the expressions of these factors 
in our patient. Immunohistochemistry was performed on 
the formaldehyde-fixed skin samples of the biopsy taken 
at the initial presentation, with antibodies against p65 
(Cell Signaling Technology, #8242), a component of NF-
κB, and CARD14 (SIGMA, HPA023388). Both p65 and 
CARD14 were only marginally expressed in the nucleus 
of keratinocytes in our patient (Fig. 2b, c). How ever, their 
expressions were more concentrated around inflammatory 
cells surrounding the dermal vasculature (Fig. 2b, c).
DISCUSSION
Apremilast is an oral PDE4 inhibitor that is currently a 
treatment option for psoriasis and psoriatic arthritis (4). 
The mode of action of apremilast is considered to be 
the upregulation of intracellular cyclic adenosine mono-
phosphate (cAMP) and thereby the suppression of NF-κB 
(4). Various types of cells, including keratinocytes, are 
regarded as targets of apremilast (5, 6). 
Although the aetiology of PRP remains unclear, excess 
activation of CARD14 and NF-κB in keratinocytes is 
suggested as a possible pathological mechanism. Muta-
tions in CARD14 are associated with hereditary forms 
of PRP (7), and such mutations result in the activation 
of NF-κB and therefore the upregulation of inflamma-
tory cytokines in keratinocytes (8). Recent studies have 
also shown an increase in CARD14 and NF-κB (p65) 
expressions in keratinocytes in sporadic cases of PRP 
(3). Therefore, we initially hypothesized that CARD14 
and p65 were also upregulated in the keratinocytes of 
our patient. However, immunohistochemistry staining 
showed that both CARD14 and p65 stained mainly in 
the nucleus of the dermal inflammatory cells rather than 
in keratinocytes. Therefore, in our patient, the activation 
of CARD14 and NF-κB in the dermal inflammatory cells 
may have been the main pathological mechanism for the 
skin inflammation. Indeed, a recent report indicates that 
CARD14 in the dermal inflammatory cells is essential in 
the development of psoriatic inflammation in mice (9). 
The activation of CARD14, not only in keratinocytes, 
but also in the dermal inflammatory cells, may play an 
important role in the pathogenesis of PRP. Apremilast 
may therefore exert its actions by inhibiting the activa-
tion of both keratinocytes and inflammatory cells in PRP.
Finding a successful treatment for PRP is often chal-
lenging in spite of the various treatment options currently 
available. While classical PRP is known to spontaneously 
regress, the timing of its resolution coinciding with the 
start of apremilast in our case suggests that apremilast 
may be effective in PRP. In keeping with our case, 2 
previous cases of sporadic PRP were treated successfully 
with apremilast (10, 11). In both cases, significant impro-
vements were evident shortly after the start of treatment 
with apremilast and no recurrence has been seen (10, 11). 
PDE4 inhibitors may therefore be considered as a new 
management option in cases of PRP that are resistant to 
mainstay treatments, such as steroids, vitamin D3 ana-
logues, salicylic acid, and retinoids.
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